Larimar Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Larimar Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript
The decision can change Larimar Therapeutics, Inc.’s market access, costs and competitive freedom.
Watch next: regulator filings, verified operating scope and liability disclosures.With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest
The story matters when it changes Larimar Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.With 45% ownership, Larimar Therapeutics, Inc. (NASDAQ:LRMR) has piqued the interest of hedge funds investors
The story matters when it changes Larimar Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest LRMR filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Larimar Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →